Underuse of Oral Anticoagulants in Privately Insured Patients with Atrial Fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to ImProve treatment with Oral AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AFib)
Several members of DiMe’s leadership participated in a study, published in the American Heart Journal, concludes that there is an unmet need for evidence-based interventions that could lead to greater use of OACs in patients with AF at risk for stroke.
